These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21833557)

  • 1. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.
    Sadar MD
    World J Urol; 2012 Jun; 30(3):311-8. PubMed ID: 21833557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
    Sadar MD
    Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
    Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
    Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor antagonists in castration-resistant prostate cancer.
    Rathkopf D; Scher HI
    Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
    Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
    J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
    Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.
    Obst JK; Tien AH; Setiawan JC; Deneault LF; Sadar MD
    Steroids; 2024 Oct; 210():109482. PubMed ID: 39053630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New hormonal therapies for castration-resistant prostate cancer.
    Mostaghel EA; Plymate S
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):625-42, x. PubMed ID: 21889725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
    Ji Y; Zhang R; Han X; Zhou J
    Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
    J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
    Ferroni C; Varchi G
    Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiandrogens in prostate cancer.
    Reid P; Kantoff P; Oh W
    Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor variants: RNA-based mechanisms and therapeutic targets.
    Tietz KT; Dehm SM
    Hum Mol Genet; 2020 Sep; 29(R1):R19-R26. PubMed ID: 32412639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
    Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
    Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.